advertisement
Hewitt AW 41
Showing records 1 to 25 | Display all abstracts from Hewitt AW106636 Cost-effectiveness of polygenic risk profiling for primary open-angle glaucoma in the United Kingdom and Australia
Liu Q
Eye 2023; 37: 2335-2343
106183 Attitudes Toward Glaucoma Genetic Risk Assessment in Unaffected Individuals
Hollitt GL
Translational vision science & technology 2022; 11: 38
106309 Association of High Polygenic Risk With Visual Field Worsening Despite Treatment in Early Primary Open-Angle Glaucoma
Siggs OM
JAMA ophthalmology 2022; 141: 73-77
105995 Specifications of the ACMG/AMP variant curation guidelines for myocilin: Recommendations from the clingen glaucoma expert panel
Burdon KP; Graham P
Human Mutation 2022; 43: 2170-2186
106309 Association of High Polygenic Risk With Visual Field Worsening Despite Treatment in Early Primary Open-Angle Glaucoma
Qassim A
JAMA ophthalmology 2022; 141: 73-77
106636 Cost-effectiveness of polygenic risk profiling for primary open-angle glaucoma in the United Kingdom and Australia
Davis J
Eye 2023; 37: 2335-2343
106183 Attitudes Toward Glaucoma Genetic Risk Assessment in Unaffected Individuals
Siggs OM
Translational vision science & technology 2022; 11: 38
106636 Cost-effectiveness of polygenic risk profiling for primary open-angle glaucoma in the United Kingdom and Australia
Han X
Eye 2023; 37: 2335-2343
106309 Association of High Polygenic Risk With Visual Field Worsening Despite Treatment in Early Primary Open-Angle Glaucoma
Han X
JAMA ophthalmology 2022; 141: 73-77
106183 Attitudes Toward Glaucoma Genetic Risk Assessment in Unaffected Individuals
Ridge B
Translational vision science & technology 2022; 11: 38
105995 Specifications of the ACMG/AMP variant curation guidelines for myocilin: Recommendations from the clingen glaucoma expert panel
Hadler J
Human Mutation 2022; 43: 2170-2186
106636 Cost-effectiveness of polygenic risk profiling for primary open-angle glaucoma in the United Kingdom and Australia
Mackey DA
Eye 2023; 37: 2335-2343
106183 Attitudes Toward Glaucoma Genetic Risk Assessment in Unaffected Individuals
Keane MC
Translational vision science & technology 2022; 11: 38
105995 Specifications of the ACMG/AMP variant curation guidelines for myocilin: Recommendations from the clingen glaucoma expert panel
Hulleman JD
Human Mutation 2022; 43: 2170-2186
106309 Association of High Polygenic Risk With Visual Field Worsening Despite Treatment in Early Primary Open-Angle Glaucoma
Marshall HN
JAMA ophthalmology 2022; 141: 73-77
106183 Attitudes Toward Glaucoma Genetic Risk Assessment in Unaffected Individuals
Mackey DA
Translational vision science & technology 2022; 11: 38
105995 Specifications of the ACMG/AMP variant curation guidelines for myocilin: Recommendations from the clingen glaucoma expert panel
Pasutto F
Human Mutation 2022; 43: 2170-2186
106309 Association of High Polygenic Risk With Visual Field Worsening Despite Treatment in Early Primary Open-Angle Glaucoma
Mullany S
JAMA ophthalmology 2022; 141: 73-77
106636 Cost-effectiveness of polygenic risk profiling for primary open-angle glaucoma in the United Kingdom and Australia
Macgregor S
Eye 2023; 37: 2335-2343
106183 Attitudes Toward Glaucoma Genetic Risk Assessment in Unaffected Individuals
Macgregor S
Translational vision science & technology 2022; 11: 38
105995 Specifications of the ACMG/AMP variant curation guidelines for myocilin: Recommendations from the clingen glaucoma expert panel
Boese EA
Human Mutation 2022; 43: 2170-2186
106309 Association of High Polygenic Risk With Visual Field Worsening Despite Treatment in Early Primary Open-Angle Glaucoma
He W
JAMA ophthalmology 2022; 141: 73-77
106636 Cost-effectiveness of polygenic risk profiling for primary open-angle glaucoma in the United Kingdom and Australia
Craig JE
Eye 2023; 37: 2335-2343
106183 Attitudes Toward Glaucoma Genetic Risk Assessment in Unaffected Individuals
Hewitt AW
Translational vision science & technology 2022; 11: 38
105995 Specifications of the ACMG/AMP variant curation guidelines for myocilin: Recommendations from the clingen glaucoma expert panel
Craig JE
Human Mutation 2022; 43: 2170-2186
